Richard S E Keefe
Biographic Data
| ID | 3811274 |
|---|---|
| NAME | Richard S E Keefe |
| GIVEN NAMES | Richard S E |
| FAMILY NAME | Keefe |
| SIGNATURE | KEEFE R S E |
| AFFILIATIONS | Icahn School of Medicine at Mount Sinai |
| ORCID | 0000-0002-0173-8897 |
| VERIFIED | Yes |
| TOTAL WORKS | 7 |
| TOTAL CITATIONS | 2 |
| WORKS AS AUTHOR | 7 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 1991 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 1 |
Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition
Cognitive impairment is a common and pervasive feature of etiologically diverse disorders of the central nervous system, and a target indication for a growing number of symptomatic and disease modifying drugs. Remotely acquired digital endpoints have been recognized for their potential in providing frequent, real-time monitoring of cognition, but their ultimate value will be determined by the reliability and sensitivity of measurement in the popu…
Persistent cannabis users show neuropsychological decline from childhood to midlife
Recent reports show that fewer adolescents believe that regular cannabis use is harmful to health. Concomitantly, adolescents are initiating cannabis use at younger ages, and more adolescents are using cannabis on a daily basis. The purpose of the present study was to test the association between persistent cannabis use and neuropsychological decline and determine whether decline is concentrated among adolescent-onset cannabis users. Participants…
Criminal Justice System Involvement Among People with Schizophrenia
The Matrics Consensus Cognitive Battery, Part 1
OBJECTIVE: The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia …
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive ol…
Refining phenotype characterization in genetic linkage studies of schizophrenia
A definitive replicable genetic linkage for a major locus underlying the susceptibility to schizophrenia has not been identified to date. Although there are several possible explanations for the failure to find linkage in schizophrenia, one major problem is that the range of phenotypic expressions of the genes for schizophrenia has not been clarified. A more refined understanding of the various phenotypic expressions of a gene related to schizoph…
The genetics of mental illness
(1991). The genetics of mental illness: An overview. Social Biology: Vol. 38, No. 3-4, pp. 1-5
Refining phenotype characterization in genetic linkage studies of schizophrenia
A definitive replicable genetic linkage for a major locus underlying the susceptibility to schizophrenia has not been identified to date. Although there are several possible explanations for the failure to find linkage in schizophrenia, one major problem is that the range of phenotypic expressions of the genes for schizophrenia has not been clarified. A more refined understanding of the various phenotypic expressions of a gene related to schizoph…
The genetics of mental illness
(1991). The genetics of mental illness: An overview. Social Biology: Vol. 38, No. 3-4, pp. 1-5
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive ol…
The Matrics Consensus Cognitive Battery, Part 1
OBJECTIVE: The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia …
Criminal Justice System Involvement Among People with Schizophrenia
Persistent cannabis users show neuropsychological decline from childhood to midlife
Recent reports show that fewer adolescents believe that regular cannabis use is harmful to health. Concomitantly, adolescents are initiating cannabis use at younger ages, and more adolescents are using cannabis on a daily basis. The purpose of the present study was to test the association between persistent cannabis use and neuropsychological decline and determine whether decline is concentrated among adolescent-onset cannabis users. Participants…
Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition
Cognitive impairment is a common and pervasive feature of etiologically diverse disorders of the central nervous system, and a target indication for a growing number of symptomatic and disease modifying drugs. Remotely acquired digital endpoints have been recognized for their potential in providing frequent, real-time monitoring of cognition, but their ultimate value will be determined by the reliability and sensitivity of measurement in the popu…
Psychiatry (7 works) · Medicine (5 works) · Psychology (5 works) · Schizophrenia research and treatment (4 works) · Clinical Psychology (3 works) · Cognition (3 works) · Antipsychotic (2 works) · Biology (2 works) · Genetics (2 works) · Internal Medicine (2 works)